Literature DB >> 2133247

Plasminogen activators and cancer.

M J Duffy1.   

Abstract

Plasminogen activator (PA) is a specific serine protease which catalyses conversion of the inactive plasminogen into the broad-spectrum protease, plasmin. PA exists in two structurally related forms known as tissue-type PA (tPA) and urokinase-type PA (uPA). Conversion of normal cells into a malignant state frequently leads to increased production of uPA. There is increasing evidence that uPA is directly involved in the process of metastasis. High levels of uPA in human breast cancers is a marker for poor prognosis. Finally, uPA may be a target for anti-metastatic agents, either by inhibition of its synthesis, inhibition of its activity or its binding to receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2133247

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  12 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

Review 2.  The role of proteolytic enzymes in cancer invasion and metastasis.

Authors:  M J Duffy
Journal:  Clin Exp Metastasis       Date:  1992-05       Impact factor: 5.150

Review 3.  The plasmin-antiplasmin system: structural and functional aspects.

Authors:  Johann Schaller; Simon S Gerber
Journal:  Cell Mol Life Sci       Date:  2010-12-07       Impact factor: 9.261

4.  Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.

Authors:  H Shiomi; Y Eguchi; T Tani; M Kodama; T Hattori
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

5.  Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.

Authors:  Jian Zhang; Sudha Sud; Kosuke Mizutani; Margaret R Gyetko; Kenneth J Pienta
Journal:  Neoplasia       Date:  2011-01       Impact factor: 5.715

6.  Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts.

Authors:  Shih-Chun Chao; Dan-Ning Hu; Pei-Yu Yang; Ching-Yang Lin; Shun-Fa Yang
Journal:  Mol Vis       Date:  2011-01-06       Impact factor: 2.367

7.  Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a).

Authors:  Rocco Romagnuolo; Santica M Marcovina; Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2014-01-29       Impact factor: 5.922

Review 8.  Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.

Authors:  S Mohanam; R E Sawaya; M Yamamoto; J M Bruner; G L Nicholson; J S Rao
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Protein C inhibitor is expressed in tubular cells of human kidney.

Authors:  K P Radtke; J A Fernández; J S Greengard; W W Tang; C B Wilson; D J Loskutoff; I Scharrer; J H Griffin
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 10.  Humoral innate immune response and disease.

Authors:  Stephanie N Shishido; Sriram Varahan; Kai Yuan; Xiangdong Li; Sherry D Fleming
Journal:  Clin Immunol       Date:  2012-06-18       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.